DexCom, Inc. (NASDAQ:DXCM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
(b)
On February 14, 2017, Jess Roper, the Senior Vice President and Chief Financial Officer of DexCom, Inc. (“DexCom”), notified DexCom of his decision to resign, effective as of April 1, 2017. Mr. Roper confirmed that his resignation did not result from a disagreement with DexCom on any matter relating to its operations, policies or practices, including its controls or financial related matters.
In connection with Mr. Roper’s resignation, DexCom intends to enter into a separation agreement with Mr. Roper that provides for (i) a lump sum cash payment equivalent to 12 months of his base salary and (ii) 12 months acceleration in the vesting of his unvested equity awards that are outstanding as of April 1, 2017, in exchange for Mr. Roper’s delivery of an effective general release and waiver of any claims against DexCom by Mr. Roper.
Upon Mr. Roper’s resignation, DexCom will appoint Kevin Sun, 39, as interim Chief Financial Officer. Mr. Sun has served as DexCom’s Vice President, Finance since February 2016, after previously serving as Senior Director of Finance from March 2014 to February 2016, Director of Finance from November 2010 to February 2014 and Senior Manager, Financial Reporting and Analysis from June 2008 to November 2010. Mr. Sun holds a B.S. in Business with a dual major in Accounting and Finance, a Masters in Strategic Management and an MBA from the Kelley School of Business at Indiana University. No new compensatory or severance arrangements were entered into in connection with Mr. Sun’s appointment as interim Chief Financial Officer.
About DexCom, Inc. (NASDAQ:DXCM)
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile. It had received Conformite Europeene Marking (CE Mark) approval for its fourth generation continuous glucose monitoring system, the DexCom G4 system, enabling commercialization of the DexCom G4 system. DexCom SHARE enables users of its G4 PLATINUM System to have their sensor glucose information remotely monitored by their family or friends. The G4 PLATINUM Receiver with Share uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient’s receiver and a mobile application on the patient’s iPhone to transmit glucose information. DexCom, Inc. (NASDAQ:DXCM) Recent Trading Information
DexCom, Inc. (NASDAQ:DXCM) closed its last trading session down -0.47 at 81.42 with 632,647 shares trading hands.
